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The circulating levels of leukotriene E4 in infants
with congenital heart defects, increased pulmon-
ary blood ￿ ow and pulmonary arterial hyper-
tension, were determined and compared with
infants with decreased pulmonary blood ￿ ow
(Tetralogy of Fallot). There was no correlation
(r = 0·38) between the pulmonary arterial pres-
sure (56 4 mmHg) and the leukotriene E4 levels
(1·37 0·67 ng/ml blood) measured in peripheral
blood samples from the hypertensive group prior
to surgery. There was considerable variation in
the detectable leukotriene E4 levels in blood
samples from different patients. The levels de-
tected in the blood samples between the two
groups of patients was similar. These data suggest
that neither the surgical repair during cardiopul-
monary bypass nor the pulmonary hypertension
appeared to modify the leukotriene E4 blood
levels in the small number of patients studied.
Key words: Pulmonary hypertension, Cardiovascular
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Introduction
The hypothesis that metabolites of the arachi-
donic acid cascade, speci￿cally products of the
5-lipoxygenase pathway, may be involved in
pulmonary hypertension was based on two
lines of evidence. First, injection of cysteinyl-
leukotrienes signi￿cantly increased pulmonary
vascular resistance in neonatal lambs1 as well as
in mature guinea-pigs and rats.2 Furthermore, in
the monkey, transient pulmonary hypertension
was also observed following leukotriene admin-
istration.3 The second line of evidence was
provided by Stenmark and coworkers4 who
detected the presence of cysteinyl-leukotrienes
in newborns with persistent pulmonary hyper-
tension. These latter observations were based
on analysis of bronchoalveolar lavage ￿uid
derived from infants with pulmonary hyper-
tension. Such data suggested indirectly that
cysteinyl-leukotrienes which are potent vaso-
constrictor agents in the human lung5 may be
associated with elevated pulmonary arterial
pressure in children.
Previous surgical reports have shown that
there are acute transitory episodes of increased
pulmonary arterial pressure in patients follow-
ing open heart surgery for correction of con-
genital heart lesions.6 Unfortunately, the
circulating levels of leukotrienes in this subset
of patients is not known. In this study, the
levels of LTE4 in blood samples derived from
infants with congenital heart defects, increased
pulmonary blood ￿ow and pulmonary hyper-
tension were determined during the surgical
intervention for correction of the heart defect
and compared with infants with decreased
pulmonary blood ￿ow. Since LTE4 is known to
be produced by the human lung in vitro7,8 and
is a stable product of the 5-lipoxygenase path-
way, the aim of the present study was to
establish whether or not circulating LTE4 was
correlated with pulmonary arterial pressure and
to determine whether the human lung in situ




Eighteen patients with congenital heart defects
(2±25 months of age) were studied. Six were
diagnosed to have regular form of Tetralogy of
Fallot, seven patients had complete atrioventri-
cular septal defect, three had truncus arteriosus
and two had ventricular septal defect. All pa-
tients with pulmonary hypertension (n = 12)
presented with heart failure despite medical
therapy support. None of them received medi-
cation that could interfere with the arachidonic
acid cascade. Haemodynamic measurements
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continuously recorded for each patient using
the Hewlett Packard 78354A monitor. Open
heart repair was performed with the aid of
hypothermic cardiopulmonary bypass. Aortic
cross-clamping with injection of blood cardio-
plegia was used during the intracardiac repair.
The mean duration of the cardiopulmonary
bypass in Fallot patients was 69 4 min and
114 9 min in pulmonary hypertension sub-
jects. None of the patients had cardiac repair
under deep hypothermic circulatory arrest.
After sternal and pericardial opening, blood
samples were drawn from the main pulmonary
artery and the left atrium. Surgery was then
conducted as usual. Prior to weaning from
cardiopulmonary bypass, monitoring lines (Sel-
dicath 3 Fr. Plastimed) were introduced in the
left atrial cavity and in the main pulmonary
artery. Whilst in the intensive care unit, blood
samples were collected from the patients via
these catheter lines.
Leukotriene E4 measurements
All blood samples (0.5 ml) were collected
directly in tubes containing methanol at the
beginning (Start) of extracorporeal circulation
(ECC), 5 min after lung reperfusion (RP) and at
the end of ECC. The tubes were stored over-
night at - 208 C. The samples were then thawed,
vortexed and centrifuged (5000 rpm for 20 min
at 48 C). The supernatant was then removed and
added to tubes containing 40 ml of methanol at
10%and this mixture was then passed through
a column (Sep-Pak C-18). The extracts contain-
ing lipids were collected on 3 ml of methanol.
These samples were then separated into equal
volume aliquots and dried using a Speed-Vac
evaporator. The residue was dissolved in mobile
phase solution of HPLC (acetonitrile/water/
acetic acid at pH5.6). This solution (20 ml) was
injected into an HPLC (Waters) for separation.
The samples were collected and quanti￿cation
was performed by EIA (Stallergens, Fresnes,
France).
Due to the complexity of the surgical inter-
vention, internal standards for LTE4 were not
performed. However, using a blood sample
obtained prior to surgery in one infant the
analytic recoveries for standard LTE4 were 78%
for 0·5 ng/ml and 82%for 1 ng/ml, demonstrat-
ing that collection of blood samples in tubes
containing methanol permitted adequate recov-
eries of LTE4. The range of LTE4 levels detected
in the peripheral blood samples was 0 to
0·76 ng/ml (Fallot patients) and 0 to 7·2 ng/ml
(pulmonary hypertension patients).
Statistical analysis
Results are expressed as means SEM. Since
the number of patients studied was limited and
the LTE4 range was large, no statistical analysis
was performed on the data. However, the data
for each patient are presented.
Results
The pulmonary arterial pressure and the quan-
tities of LTE4 detected in peripheral blood
samples derived from patients without (Fallot)
and with pulmonary hypertension (PH) prior to
surgery are shown in Table 1. There was no
correlation between the elevated preoperative
pulmonary arterial pressure and the levels of
circulating LTE4 detected in the peripheral
blood samples (r = 0·38). The LTE4 levels
detected in the infants during the course of the
surgical intervention are presented in Tables 2
and 3 as well as in Fig. 1. The LTE4 levels
measured in blood samples derived from the
pulmonary artery for the different patients
(Fallot vs. PH) were similar. Values obtained in
the samples from the left atrium in these two
groups of patients were also similar. In ￿ve
patients (PH) who were studied over the course
of 12 h the LTE4 levels were not altered when
compared with those data obtained at the
beginning of ECC.
In ￿ve of the 18 patients examined (one Fallot
and four PH), the LTE4 levels were below the
threshold level of detection. Of the 13 patients
where LTE4 levels were detectable, eight sub-
jects exhibited higher LTE4 levels in blood
samples derived from the left atrium than those
levels detected in blood samples from the
pulmonary artery during the lung reperfusion
period. In two subjects, the LTE4 levels in the
left atrium were lower than those measured in
the pulmonary artery blood samples. In two
patients no samples were obtained and in
another patient the values were the same. In
addition, the total quantities of LTE4 detected
during the surgical intervention were: Fallot,
Table 1. Pulmonary arterial pressure and circulating leuko-







Fallot 11.9 3.2 6 NM 0.44 0.12
PH 8.5 1.6 12 56 4 1.37 0.67
Values are means SEM from the number of patients studied (n).
Age at time of surgery. PH = pulmonary hypertension; PAP =
pulmonary arterial pressure (prior to surgery) and NM = not
measured. The LTE4 levels were determined in peripheral blood
samples prior to surgery.
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0·43 ng/ml blood.
Discussion
While LTE4 was detected in blood samples from
infants (72% ) an increase in the circulating
levels was not observed in those patients with
pulmonary hypertension. These data, derived
from a limited number of patients, suggested
that neither the surgical intervention nor the
pulmonary hypertension were associated with
an alteration in LTE4 blood levels.
There was considerable variation in the LTE4
levels detected in blood samples obtained from
neonates with or without pulmonary hyper-
tension. The range in the quantities of LTE4
detected was similar to those reported by other
investigators when this metabolite was meas-
ured in either urine,9- 11 bronchoalveolar
lavage12 or blood samples13 from patients with
Table 2. LTE4 levels (pg/ml) detected in blood samples obtained from infants (Fallot)
Patients Age (months) Peripheral
blood
ECC
Start Lung reperfusion End
PA LA PA LA PA LA
1 8 590 660 750 432 470 327 440
2 3.2 366 421 471 2010 1850 582 1880
3 15.8 700 1040 565 525 780 635 665
4 25.7 755 835 765 500 1105 1170 1320
5 10.4 0 0 0 0 0 0 0
6 8.5 246 224 632 NP 445 491 523
PA = pulmonary artery; LA = left atrium; 0 = below level of assay detection; NP = no sample; ECC = extracorporeal circulation; months = age
at surgery.








Start Lung reperfusion End
PA LA PA LA PA PA
1 13 83 406 188 746 149 340 138 253
2 9 60 630 312 1180 550 542 551 522
3 7.2 52 0 0 0 0 0 0 0
4 12 48 0 0 0 0 0 0 0
5 3.7 NM 155 209 603 NP NP 161 681
6 15 70 570 1086 799 413 566 NP NP
7 3.8 67 5090 6679 1610 7158 2317 2517 1389
8 4.8 NM 1217 244 1743 570 1832 206 1404
9 2.7 70 7172 5427 NP 532 6850 4350 5920
10 20.5 47 0 0 0 0 0 0 0
11 2.4 40 1170 1200 1310 801 1370 270 1500
12 7.8 50 0 0 0 0 0 0 0
PA = pulmonary artery; LA = left atrium; 0 = below level of assay detection; NP = no sample; ECC = extracorporeal circulation; NM = not










































FIG. 1. Circulating leukotriene E4 levels in infants during
open heart surgery. Measurements of LTE4 were performed
in blood samples obtained during surgery in a group of
infants without (Fallot) and with pulmonary hypertension
(PH). Blood samples were derived from either the pulmon-
ary artery or the left atrium at the beginning (START) of
extracorporeal circulation (ECC), 5 min after lung reperfu-
sion (LR) and at the END of ECC. In a limited number of
subjects (n = 5) measurements were made at 12 h post-
ECC. Values are means SEM and the number of infants
studied is presented above each bar.
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LTand pulmonary hypertension in infantsdifferent clinical pathologies. The reasons for
these variations are presently unknown but are
probably independent of the pathophysiological
condition, since control subjects (Fallot) exhibit
a similar range in LTE4 values, when compared
with values obtained in infants with pulmonary
hypertension. Furthermore, the LTE4 levels de-
tected were not correlated with the high pul-
monary arterial pressure observed in PHinfants.
These data are similar to a previous report in
adult pulmonary hypertensive patients where
other metabolites of the arachidonic acid cas-
cade were measured.14 These authors found no
correlation between the pulmonary arterial pres-
sure and thromboxane (TxB2) levels in urine
samples. These data suggest that the circulating
potent vasoconstrictor metabolites of the arachi-
donic acid pathway (TxA2 and LTE4) which are
detected in pulmonary hypertension may not be
related to the in vivo pressure modulations
reported in the pulmonary artery.
The low levels of LTE4 (28% of patients,
undetected) and the interpatient variation will
now require further investigation. First, there
may be a preferential metabolism of arachidonic
acid in different individuals. A signi￿cant mod-
i￿cation in the production/removal equilibrium
of the 5-lipoxygenase metabolites could result
in alterations in detection of the more stable
metabolite (LTE4). Therefore, the measurement
of only LTE4 in the biological samples may not
be an appropriate index of the 5-lipoxygenase
pathway activity in all patients. Unfortunately,
no data are available concerning LTC4 and LTD 4
levels in biological samples obtained from sub-
jects where no LTE4 was detected. The consid-
erable variation in the levels of LTE4 between
patients may also be related to the way LTE4 is
bound in the circulation. Unfortunately, little is
known about the ￿xation of cysteinyl-leuko-
trienes in the human circulation. Few studies
have been published dealing with the quantita-
tion of leukotrienes in human blood samples
and analysis has been essentially based on
results derived from human plasma.15 Finally, an
increase in quantities of leukotrienes may occur
in the tissue compartment rather than in the
circulation. Indeed, previous data have shown
that following an instillation of LT in the rat
lung only a small percentage could be detected
in the lavage ￿uid16 suggesting that the lung
tissue rather than the lung liquid was the
dominant compartment. Whether or not lung
tissue from pulmonary hypertensive patients
exhibits elevated levels of LTE4 has not been
reported. In order to adequately understand the
role of these potent in￿ammatory mediators in
pulmonary hypertension these issues will have
to be addressed not only in relation to this
disease but also other pathologies where leuko-
trienes have been implicated.
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